rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Filana Therapeutics, Inc.

FLNA · Nasdaq

Health CareBiotechnologyNot moving yet

FLNA stood above a rising 150-day average in 8 of the last 52 weekly readings, and has been out of that trend for the last 44 weeks. It is 42.8% below that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 44
Industry in uptrend
16% -15 in 4 wk
Insider buys, 12 months
$1.1M
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
78 (-15)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 8 of 52 weeks.

20 Apr – 19 Oct
17%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$222K$0$609KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months6
Sale orders, 12 months0
Buyers · sellers2 · 0
WhoDidSharesTraded
Richard BarryPresident & CEObought100,000at $0.9230 Sep 2026filed 1 Oct 2026
Richard BarryPresident & CEObought206,813at $0.9029 Sep 2026filed 1 Oct 2026
Richard BarryPresident & CEObought93,091at $0.8428 Sep 2026filed 30 Sep 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders78-15 on the quarter
New · exited8 · 23
Reported value$14.3M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20261,974,981$2.4M+44,038+2.3%
TWO SIGMA INVESTMENTS, LPreduced · filed 14 Aug 20261,711,358$2.0M-277,456−14.0%
MARSHALL WACE, LLPreduced · filed 13 Aug 20261,597,548$1.9M-414,995−20.6%
BlackRock, Inc.added · filed 7 Aug 20261,453,561$1.7M+39,047+2.8%
GOLDMAN SACHS GROUP INCadded · filed 14 Aug 2026668,792$796K+627,468+1518.4%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026615,510$733K+19,268+3.2%
D. E. Shaw & Co., Inc.reduced · filed 14 Aug 2026485,025$577K-74,180−13.3%
GMT Capital Corpunchanged · filed 14 Aug 2026450,100$536K00.0%
RENAISSANCE TECHNOLOGIES LLCadded · filed 13 Aug 2026389,601$464K+62,842+19.2%
Squarepoint Ops LLCnew · filed 14 Aug 2026318,380$379K+318,380
31 Mar 2023 – 30 Jun 2026
80110140Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Richard Barry Company insiderPresident & CEO · last 30 Sep 202613 · 0
Robert Eugene Anderson, Jr. Company insiderDirector · last 24 Nov 20251 · 0
Dawn Carter Bir Company insiderDirector · last 21 Oct 20250 · 0
Robert Christopher Cook Company insiderChief Operating & Legal Office · last 30 Sep 20251 · 0
Claude Nicaise Company insiderDirector · last 23 May 20250 · 0
Donnell Michael J. O. Company insiderDirector · last 23 May 20250 · 2
Patrick J. Md Phd Scannon Company insiderDirector · last 23 May 20250 · 0
Pierre Gravier Company insiderDirector · last 23 May 20250 · 0
Robert Z. Gussin Company insiderDirector · last 23 May 20250 · 0
Eric Schoen Company insiderChief Financial Officer · last 17 Apr 20254 · 1
Freda Nassif Company insiderChief Business Officer · last 17 Apr 20250 · 0
James William Kupiec Company insiderChief Medical Officer · last 29 Nov 20241 · 1

Same industry

MRNA ModernaLeading+154%
ENTX Entera BioLeading+49%
XNCR XencorLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-128%
Share count trendFY 2025 · to 9 Mar 20260.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$95.5M
Free cash flowFY 2025 · to 31 Dec 2025−$32.8M

Analyst forecasts

No analyst forecasts yet.